KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to -$740.1 million.

  • Edwards Lifesciences' Cash from Financing Activities rose 2422.44% to -$740.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$916.8 million, marking a year-over-year increase of 3565.41%. This contributed to the annual value of -$983.0 million for FY2024, which is 3825.6% down from last year.
  • According to the latest figures from Q3 2025, Edwards Lifesciences' Cash from Financing Activities is -$740.1 million, which was up 2422.44% from $52.7 million recorded in Q2 2025.
  • Over the past 5 years, Edwards Lifesciences' Cash from Financing Activities peaked at $61.7 million during Q1 2024, and registered a low of -$976.7 million during Q3 2024.
  • Over the past 5 years, Edwards Lifesciences' median Cash from Financing Activities value was -$143.3 million (recorded in 2023), while the average stood at -$241.1 million.
  • In the last 5 years, Edwards Lifesciences' Cash from Financing Activities tumbled by 125225.81% in 2022 and then skyrocketed by 15455.49% in 2025.
  • Quarter analysis of 5 years shows Edwards Lifesciences' Cash from Financing Activities stood at -$62.0 million in 2021, then crashed by 1252.26% to -$838.4 million in 2022, then surged by 50.72% to -$413.2 million in 2023, then surged by 106.92% to $28.6 million in 2024, then plummeted by 2687.76% to -$740.1 million in 2025.
  • Its Cash from Financing Activities was -$740.1 million in Q3 2025, compared to $52.7 million in Q2 2025 and -$258.0 million in Q1 2025.